

PATENT Atty. Docket No. PP016466.0002

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first-class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on Feb. 7.2006

By: Joy m. maishell

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Pablo Garcia, et al.

U.S. Application No.

10/016,604

Date Filed:

December 7, 2001

Group Art Unit:

1648

Examiner:

L. Humphrey

For:

ENDOGENOUS RETROVIRUSES UP-REGULATED IN

PROSTATE CANCER

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT TRANSMITTAL

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed is an Information Disclosure Statement and accompanying Forms PTO/SB/08A and PTO/SB/08B for the above-identified patent application.

- [X] In accordance with 37 C.F.R. \$1.97(b), no additional fee for submission of the IDS is required.
- [] In accordance with 37 C.F.R. §1.97(c), also enclosed is:
  - [] the fee of \$180.00 as set forth in 37 C.F.R. 1.17(p); or
  - [] a statement as specified in 37 C.F.R. §1.97(e).
- [] In accordance with 37 C.F.R. §1.97(d), a statement as

specified in 37 C.F.R. §1.97 (e) and the fee of \$180.00 as set forth in 37 C.F.R. §1.17(p) are also enclosed.

- in the amount of \$\_\_\_\_\_ for total [] Check No. fee is attached.
- [X] A return receipt postcard is also enclosed.
- [] Please charge \$\_ to Deposit Account No. 03-1664 for the total fee. This paper is being submitted in duplicate.

The Commissioner for Patents is hereby authorized to charge any additional fees (or credit any overpayment) associated with this communication and which may be required under 37 CFR 1.16 and 1.17 to Deposit Account No. 03-1664.

Respectfully submitted,

By:

Mei Hong

Agent for Applicants Reg. No. 55,276

Date: February 7, 2008

NOVARTIS VACCINES AND DIAGNOSTICS, INC. Corporate Intellectual Property Dept.

4560 Horton Street

Emeryville, CA 94608-2916 Telephone: (510) 923-5413 Facsimile: (510) 655-3542

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first-class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on Teo. 7, 200

By: Jan m. marshels

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Pablo Garcia, et al.

U.S. Application No.

10/016,604

Date Filed:

December 7, 2001

Group Art Unit:

1648

Examiner:

L. Humphrey

For:

ENDOGENOUS RETROVIRUSES UP-REGULATED IN

PROSTATE CANCER

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.56 AND §1.97(b) (3)

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

The document listed on the enclosed Information Disclosure Form (Form PTO/SB/08B) may be material to the examination of the above-identified patent application. Therefore, Applicant submits this document in compliance with the duty of disclosure as defined in 37 C.F.R. \$1.56 and \$1.97(b)(3). The Examiner is requested to make this citation of official record in the present application.

The present Information Disclosure Statement is being filed before the mailing date of the first Office action on the merits after

the filing of a request for continued examination under §1.114, and, therefore, no certification under 37 C.F.R. §1.97(e) or fee under 37 C.F.R. §1.17(p) is required.

The document listed on the enclosed Information Disclosure Form was cited in an examination report/communication dated August 21, 2007 in the related European Patent Application No. 01996 222.4. Pursuant to 37 C.F.R. §1.98, a copy of the document is enclosed herein

This Information Disclosure Statement under 37 C.F.R. §1.56 and \$1.97(b)(3) is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that these citations constitute prior art under 35 U.S.C. §102 or §103.

Respectfully submitted,

By:

Mei Hong

Agent for Applicants Reg. No. 55,276

Date: February 7, 2008

NOVARTIS VACCINES AND DIAGNOSTICS, INC. Corporate Intellectual Property Dept.

4560 Horton Street

Emeryville, CA 94608-2916 Telephone: (510) 923-5413 Facsimile: (510) 655-3542